Selected research
Market Structure
Global Human Coagulation Factor Ⅷ Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Human Coagulation Factor Ⅷ market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Human Coagulation Factor Ⅷ include Taibang Bio, Guangdong Shuanglin, Shanghai Laishi, GreenCross, Pfizer, Pfizer, Hualan Bio, Bayer and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Human Coagulation Factor Ⅷ market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Human Coagulation Factor Ⅷ and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Human Coagulation Factor Ⅷ revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Human Coagulation Factor Ⅷ market size, projected growth trends, production technologies, key applications, and end-use industries.
Human Coagulation Factor Ⅷ Segment by Company
Taibang Bio
Guangdong Shuanglin
Shanghai Laishi
GreenCross
Pfizer
Pfizer
Hualan Bio
Bayer
Baxter
Octapharma
Grifols
CSL Behring
Human Coagulation Factor Ⅷ Segment by Type
Recombinant Factor VIII
Human Factor VIII
Human Coagulation Factor Ⅷ Segment by Application
Relvent Bleeding Diseases
Hemophilia A
Human Coagulation Factor Ⅷ Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor Ⅷ.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Human Coagulation Factor Ⅷ in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Coagulation Factor Ⅷ industry.
Chapter 3: Detailed analysis of Human Coagulation Factor Ⅷ companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Coagulation Factor Ⅷrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Factor VIII
- Human Factor VIII
Applications
- Relvent Bleeding Diseases
- Hemophilia A
Companies covered
- Taibang Bio
- Guangdong Shuanglin
- Shanghai Laishi
- GreenCross
- Pfizer
- Pfizer
- Hualan Bio
- Bayer
- Baxter
- Octapharma
- Grifols
- CSL Behring
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Human Coagulation Factor Ⅷ Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Recombinant Factor VIII
- 1.2.3 Human Factor VIII
- 1.3 Market Analysis by Application
- 1.3.1 Global Human Coagulation Factor Ⅷ Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Relvent Bleeding Diseases
- 1.3.3 Hemophilia A
- 1.4 Global Market Growth Prospects
- 1.5 Global Human Coagulation Factor Ⅷ Growth Trends by Region
- 1.5.1 Global Human Coagulation Factor Ⅷ Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Human Coagulation Factor Ⅷ Market Size by Region (2021-2026)
- 1.5.3 Human Coagulation Factor Ⅷ Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Human Coagulation Factor Ⅷ Market Dynamics
- 2.1 Human Coagulation Factor Ⅷ Industry Trends
- 2.2 Human Coagulation Factor Ⅷ Industry Drivers
- 2.3 Human Coagulation Factor Ⅷ Industry Opportunities and Challenges
- 2.4 Human Coagulation Factor Ⅷ Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Human Coagulation Factor Ⅷ Revenue by Company (2021-2026)
- 3.2 Global Human Coagulation Factor Ⅷ Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Human Coagulation Factor Ⅷ Key Company Head office and Area Served
- 3.4 Global Human Coagulation Factor Ⅷ Company, Product Type & Application
- 3.5 Global Human Coagulation Factor Ⅷ Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Human Coagulation Factor Ⅷ Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Human Coagulation Factor Ⅷ Players Market Share by Revenue in 2025
- 3.6.3 2025 Human Coagulation Factor Ⅷ Tier 1, Tier 2, and Tier 3
4 Human Coagulation Factor Ⅷ Market by Type
- 4.1 Global Human Coagulation Factor Ⅷ Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Human Coagulation Factor Ⅷ Market Size by Type (2021-2032)
- 4.3 Global Human Coagulation Factor Ⅷ Market Size Share by Type (2021-2032)
5 Human Coagulation Factor Ⅷ Market by Application
- 5.1 Global Human Coagulation Factor Ⅷ Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Human Coagulation Factor Ⅷ Market Size by Application (2021-2032)
- 5.3 Global Human Coagulation Factor Ⅷ Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Taibang Bio
- 6.1.1 Taibang Bio Company Information
- 6.1.2 Taibang Bio Business Overview
- 6.1.3 Taibang Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Taibang Bio Human Coagulation Factor Ⅷ Product Portfolio
- 6.1.5 Taibang Bio Recent Developments
- 6.2 Guangdong Shuanglin
- 6.2.1 Guangdong Shuanglin Company Information
- 6.2.2 Guangdong Shuanglin Business Overview
- 6.2.3 Guangdong Shuanglin Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Guangdong Shuanglin Human Coagulation Factor Ⅷ Product Portfolio
- 6.2.5 Guangdong Shuanglin Recent Developments
- 6.3 Shanghai Laishi
- 6.3.1 Shanghai Laishi Company Information
- 6.3.2 Shanghai Laishi Business Overview
- 6.3.3 Shanghai Laishi Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Shanghai Laishi Human Coagulation Factor Ⅷ Product Portfolio
- 6.3.5 Shanghai Laishi Recent Developments
- 6.4 GreenCross
- 6.4.1 GreenCross Company Information
- 6.4.2 GreenCross Business Overview
- 6.4.3 GreenCross Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 GreenCross Human Coagulation Factor Ⅷ Product Portfolio
- 6.4.5 GreenCross Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Pfizer
- 6.6.1 Pfizer Company Information
- 6.6.2 Pfizer Business Overview
- 6.6.3 Pfizer Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
- 6.6.5 Pfizer Recent Developments
- 6.7 Hualan Bio
- 6.7.1 Hualan Bio Company Information
- 6.7.2 Hualan Bio Business Overview
- 6.7.3 Hualan Bio Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Hualan Bio Human Coagulation Factor Ⅷ Product Portfolio
- 6.7.5 Hualan Bio Recent Developments
- 6.8 Bayer
- 6.8.1 Bayer Company Information
- 6.8.2 Bayer Business Overview
- 6.8.3 Bayer Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Bayer Human Coagulation Factor Ⅷ Product Portfolio
- 6.8.5 Bayer Recent Developments
- 6.9 Baxter
- 6.9.1 Baxter Company Information
- 6.9.2 Baxter Business Overview
- 6.9.3 Baxter Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Baxter Human Coagulation Factor Ⅷ Product Portfolio
- 6.9.5 Baxter Recent Developments
- 6.10 Octapharma
- 6.10.1 Octapharma Company Information
- 6.10.2 Octapharma Business Overview
- 6.10.3 Octapharma Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Octapharma Human Coagulation Factor Ⅷ Product Portfolio
- 6.10.5 Octapharma Recent Developments
- 6.11 Grifols
- 6.11.1 Grifols Company Information
- 6.11.2 Grifols Business Overview
- 6.11.3 Grifols Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Grifols Human Coagulation Factor Ⅷ Product Portfolio
- 6.11.5 Grifols Recent Developments
- 6.12 CSL Behring
- 6.12.1 CSL Behring Company Information
- 6.12.2 CSL Behring Business Overview
- 6.12.3 CSL Behring Human Coagulation Factor Ⅷ Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 CSL Behring Human Coagulation Factor Ⅷ Product Portfolio
- 6.12.5 CSL Behring Recent Developments
7 North America
- 7.1 North America Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 7.2 North America Human Coagulation Factor Ⅷ Market Size by Type
- 7.2.1 North America Human Coagulation Factor Ⅷ Market Size by Type (2021-2026)
- 7.2.2 North America Human Coagulation Factor Ⅷ Market Size by Type (2027-2032)
- 7.2.3 North America Human Coagulation Factor Ⅷ Market Share by Type (2021-2032)
- 7.3 North America Human Coagulation Factor Ⅷ Market Size by Application
- 7.3.1 North America Human Coagulation Factor Ⅷ Market Size by Application (2021-2026)
- 7.3.2 North America Human Coagulation Factor Ⅷ Market Size by Application (2027-2032)
- 7.3.3 North America Human Coagulation Factor Ⅷ Market Share by Application (2021-2032)
- 7.4 North America Human Coagulation Factor Ⅷ Market Size by Country
- 7.4.1 North America Human Coagulation Factor Ⅷ Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 7.4.3 North America Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 7.4.4 North America Human Coagulation Factor Ⅷ Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 8.2 Europe Human Coagulation Factor Ⅷ Market Size by Type
- 8.2.1 Europe Human Coagulation Factor Ⅷ Market Size by Type (2021-2026)
- 8.2.2 Europe Human Coagulation Factor Ⅷ Market Size by Type (2027-2032)
- 8.2.3 Europe Human Coagulation Factor Ⅷ Market Share by Type (2021-2032)
- 8.3 Europe Human Coagulation Factor Ⅷ Market Size by Application
- 8.3.1 Europe Human Coagulation Factor Ⅷ Market Size by Application (2021-2026)
- 8.3.2 Europe Human Coagulation Factor Ⅷ Market Size by Application (2027-2032)
- 8.3.3 Europe Human Coagulation Factor Ⅷ Market Share by Application (2021-2032)
- 8.4 Europe Human Coagulation Factor Ⅷ Market Size by Country
- 8.4.1 Europe Human Coagulation Factor Ⅷ Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 8.4.3 Europe Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 8.4.4 Europe Human Coagulation Factor Ⅷ Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 9.2 China Human Coagulation Factor Ⅷ Market Size by Type
- 9.2.1 China Human Coagulation Factor Ⅷ Market Size by Type (2021-2026)
- 9.2.2 China Human Coagulation Factor Ⅷ Market Size by Type (2027-2032)
- 9.2.3 China Human Coagulation Factor Ⅷ Market Share by Type (2021-2032)
- 9.3 China Human Coagulation Factor Ⅷ Market Size by Application
- 9.3.1 China Human Coagulation Factor Ⅷ Market Size by Application (2021-2026)
- 9.3.2 China Human Coagulation Factor Ⅷ Market Size by Application (2027-2032)
- 9.3.3 China Human Coagulation Factor Ⅷ Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 10.2 Asia Human Coagulation Factor Ⅷ Market Size by Type
- 10.2.1 Asia Human Coagulation Factor Ⅷ Market Size by Type (2021-2026)
- 10.2.2 Asia Human Coagulation Factor Ⅷ Market Size by Type (2027-2032)
- 10.2.3 Asia Human Coagulation Factor Ⅷ Market Share by Type (2021-2032)
- 10.3 Asia Human Coagulation Factor Ⅷ Market Size by Application
- 10.3.1 Asia Human Coagulation Factor Ⅷ Market Size by Application (2021-2026)
- 10.3.2 Asia Human Coagulation Factor Ⅷ Market Size by Application (2027-2032)
- 10.3.3 Asia Human Coagulation Factor Ⅷ Market Share by Application (2021-2032)
- 10.4 Asia Human Coagulation Factor Ⅷ Market Size by Country
- 10.4.1 Asia Human Coagulation Factor Ⅷ Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 10.4.3 Asia Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 10.4.4 Asia Human Coagulation Factor Ⅷ Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Type
- 11.2.1 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Application
- 11.3.1 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country
- 11.4.1 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Human Coagulation Factor Ⅷ Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst